Ga68 PSMA PET-CT has the capacity to revolutionize the diagnostic paradigm by providing clinicians with unprecedented insights into disease extent and treatment response, potentially reshaping therapeutic decision making in prostate cancer management. The gene discussed is FOLH1; the disease is prostate carcinoma.